- Open Access
Association between STAT3 gene Polymorphisms and Crohn’s diseasesusceptibility: a case–control study in a Chinese Han population
Diagnostic Pathology volume 9, Article number: 104 (2014)
Crohn’s disease (CD) is an immune-related disease with geneticpredisposition. This study aimed to investigate the association of threepolymorphisms in the signal transducer and activator of transcription 3(STAT3) gene with CD risk in a Chinese population.
We conducted a hospital-based case–control study involving 232 CDpatients and 272 controls. Genotyping was performed using polymerase chainreaction with sequence-specific primer method. Statistical analyses wereconducted using logistic regression and genotype risk scoring.
Significant differences were found between patients and controls inallele/genotype distributions of rs744166(P allele = 0.0008;P genotype = 0.003) and allele distributions ofrs4796793 (P = 0.03). The risk for CD associated withthe rs744166-A mutant allele decreased by 37% [95% confidence interval (CI):0.48–0.83] under the additive model, 39% (95% CI: 0.43–0.81)under the dominant model and 57% (95% CI: 0.24–0.77) under therecessive model. Carriers of the rs4796793-G mutant allele exhibited 25%(95% CI: 0.58–0.98; P = 0.03) and 47% (95% CI:0.30–0.95) decreased risks of developing CD under the additive andrecessive models, respectively.
STAT3 rs744166 and rs4796793 polymorphisms may be associated with CDoccurrence and used as a predictive factor of CD in Chinese Hanpopulations.
The virtual slide(s) for this article can be found here:http://diagnosticpathology.slidepath.com/webViewer.php?snapshotId=1297687014
Crohn’s disease (CD) and ulcerative colitis (UC) are inflammatory boweldiseases (IBDs). The etiology and pathogenesis of CD are not completely understood.However, familial aggregation and twin studies report that patients with CD carrystrong genetic predisposition . Several studies also strongly suggest that CD results from a combinationof factors, such as commensal bacteria, food antigens, immunologic factors andmultiple genetic factors [2, 3]. The signal transducer and activator of transcription 3 (STAT3) gene is apotential candidate gene for CD for several reasons. STAT3 is a member of STATfamily, which possesses an important function in the development of human immunesystem and haematopoiesis. This gene has been associated with the signaltransduction pathway of multiple cytokines, including IL-2/γc, IL-6/gp130, IFNand IL-10 families, as well as IL-12, IL- 23, Flt3 ligand, M-CSF, G-CSF, leptin andgrowth hormone [4–9]. Several studies have highlighted that the STAT3 signaling pathway isimportant in the occurrence and development of IBD both in patients and animalmodels [10–13].
In 2008, Barrett et al.  reported that the STAT3 locus is significantly associated with CDsusceptibility in a genome-wide association study (GWAS). Since then, a number ofstudies have demonstrated that the polymorphisms of STAT3 are associated with CD aswell as UC, but their results are not consistent in different population cohorts [15–20]. Therefore, we performed an analysis on three polymorphisms (rs2293152,rs4796793 and rs744166) of STAT3 and CD in Chinese Han population.
Patient and control subjects
This hospital-based case–control study involved 232 CD patients and 272healthy controls of Chinese Han population recruited from the Department ofGastroenterology of Ruijin Hospital, which is connected with the ShanghaiJiaotong University School of Medicine between January 2009 and December 2010.Senior physicians diagnosed all patients based on clinical, endoscopic,radiological and histopathological findings in accordance with previouslyestablished international criteria . All patients were followed up at least for 1 year andregistered with an integrated clinical and epidemiological registry. Controlswere randomly selected from healthy persons under routine health screening. Thepresent study was performed in accordance with the principles of Declaration ofHelsinki and approved by the Research Ethics Committee of Ruijin Hospital,Shanghai, China. Informed consent was obtained from all subjects before bloodsampling was carried out.
Genomic DNA was isolated from Ethylene Diamine Tetraacetic Acid (EDTA) peripheralblood using the QIAamp blood extraction kit (Qiagen, Hilden, Germany) followingthe manufacturer’s instructions. All DNA samples were genotyped for singlenucleotide polymorphisms by polymerase chain reaction with sequence-specificprimers (PCR-SSPs). All primers for the PCR-SSPs were designed using the genomicsequences in GenBank (http://www.ncbi.nlm.nih.gov). The primersequences are listed in Table 1. The amplifiedproducts were assessed for the presence/absence of PCR amplicons specific toparticular alleles using a standard 2% agarose gel electrophoresis, followed byethidium-bromide staining. About 10% of the samples were then confirmed bysequencing.
For continuous and categorical variables, unpaired t-test andχ2 were conducted to compare CD patients and controls, respectively.To avoid gross genotyping error, all polymorphisms were evaluated forconsistency with Hardy–Weinberg equilibrium on a contingency table ofobserved-versus-predicted genotype frequencies by using Pearson χ2 test or Fisher's exact test. Genotypes were compared by logisticregression analysis under assumptions of additive, dominant and recessive modelsof inheritance. A P < 0.05 was considered statisticallysignificant.
Table 2 shows detailed information of patients andcontrols. Cases and controls were well matched by age and gender distribution.
The frequencies and distributions of alleles and genotypes at rs2293152, rs4796793and rs744166 STAT3 were identified and compared between CD patients and controls.The genotype distributions of the three polymorphisms of STAT3 were inHardy–Weinberg equilibrium in control groups(P > 0.05).
Table 3 shows that a significant difference was observedfor rs744166 between CD patients and controls both in allele and genotypedistributions (P allele = 0.0008, andP genotype = 0.003). A significant decreased risk was identifiedfor rs744166 in association with CD under the additive [odds ratio(OR) = 0.63; 95% confidence interval (CI): 0.48–0.83], dominant(OR = 0.61; 95% CI: 0.43–0.81) and recessive(OR = 0.43; 95% CI: 0.24–0.77) models.
As for rs4796793, a significant difference was observed between the two groups inallele but not in genotype distribution (P allele = 0.03 andP genotype = 0.07). Meanwhile, a significant decreased riskwas found in association with CD under the additive (OR = 0.75; 95% CI:0.58–0.98) and recessive (OR = 0.53; 95% CI: 0.30–0.95)models, whereas no significant association was detected under the dominant model(OR = 0.76; 95% CI: 0.57–1.09).
No significant difference was observed in the genotype and allele distributions ofrs2293152 between CD patients and controls. This result also agrees under theassumptions of the additive (OR = 0.94; 95% CI: 0.73–1.23),dominant (OR = 1.19; 95% CI: 0.80–1.77) and recessive(OR = 0.66; 95% CI: 0.42–1.05) models.
CD is a relapsing inflammatory condition of gastrointestinal mucosal damage withcharacteristic extra-intestinal manifestations [22, 23]. CD is widely known as an immune-related disease with geneticpredisposition. Given the importance of immunity in CD, investigations onCD-susceptibility genes that involve immunity have attracted considerable attention [24, 25].
The STAT3 gene is located on chromosome 17q21. Its protein product is a member of theSTAT protein family that performs a dual function: signal transduction andtranscription activation. STAT3 is widely expressed and a latent cytoplasmictranscription factor that relays signals from the cell membrane directly to thenucleus. STAT3 becomes activated through phosphorylation on tyrosine as aDNA-binding protein in response to a variety of stimuli and mediates the expressionof a variety of genes. Thus, STAT3 possesses a key function in many biologicalpathways crucial to cell function, including proliferation, migration, survival anddifferentiation . Several studies indicated that STAT3 activation plays distinctlydifferent roles between innate and acquired immune responses in colitis, that is,activation of STAT3 in innate immune cells enhances mucosal barrier function andSTAT3 activation in T-cells exacerbates colitis [11, 12]. A number of studies also suggest that polymorphisms of STAT3 areassociated with the susceptibility of CD or UC in some population cohorts [15–20].
We examined three polymorphisms of STAT3 in 232 CD patients and 272 normal controlsof Chinese Han population. Results revealed that both the STAT3 gene alleles ofrs4796793G and rs744166C reduced the risk of CD occurrence and may have a protectivefunction in CD. To the authors' knowledge, this is the pilot study that explored thegenetic susceptibility of STAT3 gene to CD in a Chinese population.
The rs744166, which was first identified as an important candidate susceptibilitylocus for CD in a GWAS research , was confirmed in a Chinese population in this study. Our results are inagreement with those previously published data in a New Zealand population . They found a significant decrease in the frequency of the G allele ofrs744166 in CD patients compared with controls (OR = 0.76, 95%CI = 0.61–0.95, P = 0.013), and G allele maybe protective against CD. However, Franke et al.  failed to replicate the association between rs744166 and CD risk in aGerman population. This discrepancy may be mostly due to the heterogeneous geneticpredispositions in people of different ethnicities. The genetic markers inpredisposition to IBD vary across geographical and racial groups. In our previousmeta-analyses, the CD14 gene C-260 T polymorphism exhibits remarkableheterogeneity with UC across ethnic groups, which is significant in Asians but notin Caucasians . However, given the relatively small samples in this study, more studiesare required to reliably quantify the effect of rs744166.
rs2293152, a STAT3 variant, has been reported to be significantly associated with CDin Japanese population . This variant did not show significant association between CD patient andnormal control groups in this study. Sample size may be one of the majordeterminants because both studies (Sato’s research and our study) selectedEast Asia population. Sato’s study only enrolled 83 CD cases and 200 healthycontrols, whereas our study included 232 CD cases and 272 normal controls. Given thelarger sample size, our result seems more reliable. We could not exclude thedifferent population results in different genetic backgrounds.
In the present study, a new candidate locus, rs4796793, was found, which wasassociated with CD in Chinese population. This association is not reported in otherstudies. Therefore, further studies should be carried out to verify this associationusing a large sample size from different ethnic origins and biological research.
This study has some drawbacks. First, the sample size was not very large; thus, moreSNP sites for pair-loci D'/r2 value analysis and haplotype analysis on a largernumber of Chinese subjects and on other ethnicities are necessary to confirm theassociation more clearly. Second, we only revealed limited polymorphisms of STAT3gene associated with susceptibility to CD, and other unidentified polymorphisms,which influenced the development of CD, may still exist. Third, our results werebased on unadjusted estimates. STAT3 gene polymorphisms of rs4796793 and rs744166individually make a protective contribution against CD, but whether thepolymorphisms integrated with other risk factors will change the prediction requiresadditional research. Thus, a more precise analysis should be conducted withindividual data, which would allow for the adjustment by other co-varieties, such asage, gender, lifestyle and other genetic factors.
In conclusion, this study is the first to demonstrate the single-marker associationof STAT3 with CD susceptibility in the Chinese Han population. We confirmed thatSTAT3 rs744166 and rs4796793 polymorphisms were associated with CD occurrence andused as a predictive factor of CD in Chinese Han populations.However, the diversegenetic profiles across different ethnic groups remain unclear.
Signal transducer and activator of transcription 3
Inflammatory bowel disease
Genome-wide association study
Ethylene Diamine Tetraacetic Acid
Polymerase chain reaction with sequence-specific primers
Zheng CQ, Hu GZ, Zeng ZS, Lin LJ, Gu GG: Progress in searching for susceptibility gene for inflammatory bowel diseaseby positional cloning. World J Gastroenterol. 2003, 9 (8): 1646-1656.
Molodecky NA, Kaplan GG: Environmental risk factors for inflammatory bowel disease. Gastroenterology hepatology(NY). 2010, 6 (5): 339-346.
Cho JH: The genetics and immunopathogenesis of inflammatory bowel disease. Nat Rev Immunol. 2008, 8 (6): 458-466. 10.1038/nri2340.
Murray PJ: The JAK-STAT signaling pathway: input and output integration. J Immunol. 2007, 178 (5): 2623-2629. 10.4049/jimmunol.178.5.2623.
O'Shea JJ, Murray PJ: Cytokine signaling modules in inflammatory responses. Immunity. 2008, 28 (4): 477-487. 10.1016/j.immuni.2008.03.002.
Akira S: Roles of STAT3 defined by tissue-specific gene targeting. Oncogene. 2000, 19 (21): 2607-2611. 10.1038/sj.onc.1203478.
Takeda K, Clausen BE, Kaisho T, Tsujimura T, Terada N, Förster I, Akira S: Enhanced Th1 activity and development of chronic enterocolitis in mice devoidof Stat3 in macrophages and neutrophils. Immunity. 1999, 10 (1): 39-49. 10.1016/S1074-7613(00)80005-9.
Stumhofer JS, Silver JS, Laurence A, Porrett PM, Harris TH, Turka LA, Ernst M, Saris CJ, O'Shea JJ, Hunter CA: Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin10. Nat Immunol. 2007, 8 (12): 1363-1371. 10.1038/ni1537.
Laouar Y, Welte T, Fu XY, Flavell RA: STAT3 is required for Flt3L-dependent dendritic cell differentiation. Immunity. 2003, 19 (6): 903-912. 10.1016/S1074-7613(03)00332-7.
Suzuki A, Hanada T, Mitsuyama K, Yoshida T, Kamizono S, Hoshino T, Kubo M, Yamashita A, Okabe M, Takeda K, Akira S, Matsumoto S, Toyonaga A, Sata M, Yoshimura A: CIS3/SOCS3/SSI3 plays a negative regulatory role in STAT3 activation andintestinal inflammation. J Exp Med. 2001, 193 (4): 471-481. 10.1084/jem.193.4.471.
Musso A, Dentelli P, Carlino A, Chiusa L, Repici A, Sturm A, Fiocchi C, Rizzetto M, Pegoraro L, Sategna-Guidetti C, Brizzi MF: Signal transducers and activators of transcription 3 signaling pathway: anessential mediator of inflammatory bowel disease and other forms ofintestinal inflammation. Inflamm Bowel Dis. 2005, 11 (2): 91-98. 10.1097/00054725-200502000-00001.
Lovato P, Brender C, Agnholt J, Kelsen J, Kaltoft K, Svejgaard A, Eriksen KW, Woetmann A, Ødum N: Constitutive STAT3 activation in intestinal T cells from patients withCrohn's disease. J Biol Chem. 2003, 278 (19): 16777-16781. 10.1074/jbc.M207999200.
Li Y, de Haar C, Peppelenbosch MP, van der Woude CJ: New insights into the role of STAT3 in IBD. Inflamm Bowel Dis. 2012, 18 (6): 1177-1183. 10.1002/ibd.21884.
Barrett JC, Hansoul S, Nicolae DL, Cho JH, Duerr RH, Rioux JD, Brant SR, Silverberg MS, Taylor KD, Barmada MM, Bitton A, Dassopoulos T, Datta LW, Green T, Griffiths AM, Kistner EO, Murtha MT, Regueiro MD, Rotter JI, Schumm LP, Steinhart AH, Targan SR, Xavier RJ, Genetics Consortium NIDDKIBD, Libioulle C, Sandor C, Lathrop M, Belaiche J, Dewit O, Gut I, et al.: Genome-wide association defines more than 30 distinct susceptibility loci forCrohn's disease. Nat Genet. 2008, 40 (8): 955-962. 10.1038/ng.175.
Franke A, Balschun T, Karlsen TH, Hedderich J, May S, Lu T, Schuldt D, Nikolaus S, Rosenstiel P, Krawczak M, Schreiber S: Replication of signals from recent studies of Crohn's disease identifiespreviously unknown disease loci for ulcerative colitis. Nat Genet. 2008, 40 (6): 713-715. 10.1038/ng.148.
Sato K, Shiota M, Fukuda S, Iwamoto E, Machida H, Inamine T, Kondo S, Yanagihara K, Isomoto H, Mizuta Y, Kohno S, Tsukamoto K: Strong evidence of a combination polymorphism of the tyrosine kinase 2 geneand the signal transducer and activator of transcription 3 gene as aDNA-based biomarker for susceptibility to Crohn's disease in the Japanesepopulation. J Clin Immunol. 2009, 29 (6): 815-825. 10.1007/s10875-009-9320-x.
Ferguson LR, Han DY, Fraser AG, Huebner C, Lam WJ, Morgan AR, Duan H, Karunasinghe N: Genetic factors in chronic inflammation: single nucleotide polymorphisms inthe STAT-JAK pathway, susceptibility to DNA damage and Crohn's disease in aNew Zealand population. Mutat Res. 2010, 690 (1–2): 108-115.
Cénit MC, Alcina A, Márquez A, Mendoza JL, Díaz-Rubio M, de las Heras V, Izquierdo G, Arroyo R, Fernández O, de la Concha EG, Matesanz F, Urcelay E: STAT3 locus in inflammatory bowel disease and multiple sclerosissusceptibility. Genes Immun. 2010, 11 (3): 264-268. 10.1038/gene.2010.10.
Peter I, Mitchell AA, Ozelius L, Erazo M, Hu J, Doheny D, Abreu MT, Present DH, Ullman T, Benkov K, Korelitz BI, Mayer L, Desnick RJ, New York Crohn's Disease Working Group: Evaluation of 22 genetic variants with Crohn's disease risk in the AshkenaziJewish population: a case–control study. BMC Med Genet. 2011, 12: 63-
Polgar N, Csongei V, Szabo M, Zambo V, Melegh BI, Sumegi K, Nagy G, Tulassay Z, Melegh B: Investigation of JAK2, STAT3 and CCR6 polymorphisms and their gene-geneinteractions in inflammatory bowel disease. Int J Immunogenet. 2012, 39 (3): 247-252. 10.1111/j.1744-313X.2012.01084.x.
Ouyang Q, Tandon R, Goh KL, Pan GZ, Fock KM, Fiocchi C, Lam SK, Xiao SD: Management consensus of inflammatory bowel disease for the Asia-Pacificregion. J Gastroenterol Hepatol. 2006, 21 (12): 1772-1782. 10.1111/j.1440-1746.2006.04674.x.
Matalka II, Al-Omari FA, Salama RM, Mohtaseb AH: A novel approach for quantitative assessment of mucosal damage ininflammatory bowel disease. Diagnostic Pathology. 2013, 8: 156-10.1186/1746-1596-8-156.
Larsen EP, Bayat A, Vyberg M: Small duct autoimmune sclerosing cholangitis and Crohn colitis in a10-year-old child. A case report and review of the literature. Diagnostic Pathology. 2012, 7: 100-10.1186/1746-1596-7-100.
Wang ZT, Hu JJ, Fan R, Zhou J, Zhong J: RAGE gene three polymorphisms with Crohn's disease susceptibility in ChineseHan population. World J Gastroenterol. 2014, 20 (9): 2397-2402. 10.3748/wjg.v20.i9.2397.
Wang L, Wang ZT, Hu JJ, Fan R, Zhou J, Zhong J: Polymorphisms of the vitamin D receptor gene and the risk of inflammatorybowel disease: a meta-analysis. Genet Mol Res. 2014, 13 (2): 2598-2610. 10.4238/2014.April.8.2.
Levy DE, Darnell JJ: Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol. 2002, 3 (9): 651-662. 10.1038/nrm909.
Wang Z, Hu J, Fan R, Zhou J, Zhong J: Association between CD14 gene C-260 T polymorphism and inflammatorybowel disease: a meta-analysis. PLoS One. 2012, 7: e45144-10.1371/journal.pone.0045144.
The authors declare that they have no competing interests.
ZTW, BX, HXZ and J. Zhong conceived and designed the study. ZTW, HXZ, carried out theexperiments and drafted the manuscript. RF, J. Zhou participated in the statisticalanalysis. All authors read and approved the final manuscript.
Zhengting Wang, Bin Xu contributed equally to this work.
About this article
Cite this article
Wang, Z., Xu, B., Zhang, H. et al. Association between STAT3 gene Polymorphisms and Crohn’s diseasesusceptibility: a case–control study in a Chinese Han population. Diagn Pathol 9, 104 (2014). https://doi.org/10.1186/1746-1596-9-104
- Crohn’s diseases
- Association study